• support@madhedgefundtrader.com
  • Member Login
Mad Hedge Fund Trader
  • Home
  • About
  • Store
  • Luncheons
  • Testimonials
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
Mad Hedge Fund Trader

March 28, 2019 - Quote of the Day

Tech Letter

“Ultimately, what any company does when it is successful is merely a lagging indicator of its existing culture.” – Said CEO of Microsoft Satya Nadella

https://www.madhedgefundtrader.com/wp-content/uploads/2019/03/satya.png 358 412 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-03-28 03:05:492019-07-10 21:38:10March 28, 2019 - Quote of the Day
Mad Hedge Fund Trader

Mad Hedge Hot Tips for March 27, 2019

Hot Tips

Mad Hedge Hot Tips
March 27, 2019
Fiat Lux

The Five Most Important Things That Happened Today
(and what to do about them)

 

1) The Global Bond Short Covering Panic Continues, with ten-year US Treasury yields dropping to an eye-popping 2.37%. Slowing global growth is to blame. Did I hear the word “refi”? Click here.

2) Apple Violates QUALCOMM Patent, rules a judge, and (AAPL) tanks. The battle continues. Click here.

3) FinTech is on Fire, as legacy banks die a death of a thousand cuts, hobbled by the cost of their massive branch networks and lagging technology. Is it time to take another look at the FinTech ETF (FINX)? Click here.

4) Mad Hedge Hits New All-Time High, with 2019 performance hitting 15% this morning. More to come. Going 100% cash by the April 18 options expiration. Click here.

5) Centene (CNC) Buys WellCare (WCG) for $15 billion. Healthcare is the last fragmented industry left so you can expect vastly accelerated M&A in the future. If you can’t compete under “single payer” you’ll soon be out of business. Every stock is now a lottery ticket. Click here.
 
Published today in the Mad Hedge Global Trading Dispatch and Mad Hedge Technology Letter:

(JUMP ON THE VERTEX BANDWAGON),

(VRTX), (CRSP),

(MAD HEDGE FUND TRADER CELEBRATES ITS 11-YEAR ANNIVERSARY)

(THE DEATH OF ANOTHER STARTUP)

(WINE.L)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-03-27 11:34:062019-03-27 11:34:06Mad Hedge Hot Tips for March 27, 2019
Mad Hedge Fund Trader

March 27, 2019 - MDT Alert (NVDA)

MDT Alert

While the Diary of a Mad Hedge Fund Trader focuses on investment over a one week to the six-month time frame, Mad Day Trader, provided by Bill Davis, will exploit money-making opportunities over a brief ten minute to three-day window. It is ideally suited for day traders, but can also be used by long-term investors to improve market timing for entry and exit points. Read more

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-03-27 10:50:332019-03-27 10:50:33March 27, 2019 - MDT Alert (NVDA)
Mad Hedge Fund Trader

March 27, 2019 - MDT Pro Tips A.M.

MDT Alert

While the Diary of a Mad Hedge Fund Trader focuses on investment over a one week to a six-month time frame, Mad Day Trader, provided by Bill Davis, will exploit money-making opportunities over a brief ten minute to three-day window. It is ideally suited for day traders, but can also be used by long-term investors to improve market timing for entry and exit points. Read more

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-03-27 08:40:362019-03-27 08:40:36March 27, 2019 - MDT Pro Tips A.M.
Mad Hedge Fund Trader

March 27, 2019

Diary, Newsletter, Summary

Global Market Comments
March 27, 2019
Fiat Lux

Featured Trade:
(JUMP ON THE VERTEX BANDWAGON),
(VRTX), (CRSP),
(MAD HEDGE FUND TRADER CELEBRATES ITS 11-YEAR ANNIVERSARY)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-03-27 01:08:342019-03-26 18:15:41March 27, 2019
Mad Hedge Fund Trader

March 27, 2019

Tech Letter

Mad Hedge Technology Letter
March 27, 2019
Fiat Lux

Featured Trade:

(THE DEATH OF ANOTHER STARTUP)
(WINE.L)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-03-27 01:07:542019-07-10 21:38:16March 27, 2019
Mad Hedge Fund Trader

Jump on the Vertex Bandwagon

Diary, Newsletter

The biotech industry has at least 500 stocks listed on the market today. These companies range from huge biotech firms with several blockbuster drugs to humble money-losing startups still on the lookout for their first big break.

Among these companies, Vertex Pharmaceuticals Incorporated (VRTX) presents a compelling case that could attract investors.

Recent developments on Vertex's triple-combination treatment for cystic fibrosis (CF) have been predicted to spur the company's revenues this year in a major way. If the results of the studies turn out successful, then Vertex is on the verge of becoming the sole treatment provider to at least 90% of the people suffering from this severe genetic condition. That’s a nice monopoly to have.

While the recent developments have yet to aggressively show its effect in Vertex stock, the company has already recorded an impressive 160% growth since 2017 and this is anticipated to go higher in the years to come.

At present, the annual revenue of Vertex is recorded as $3 billion, while major competitors like Pfizer has $53.4 billion, Bristol-Myers Squibb has $22.6 billion, and Novartis has $51 billion. In order words, there is plenty of room to grow.

Just how far can Vertex shares go?

Let's take a look at previous reports on the company. Its December 2018 financial report reveals that its earnings per share jumped by 113% year-over-year to $1.3. Its quarterly revenues increased by 40% and reached $869.44 million -- a gigantic 39.7% leap from the $622.63 million it achieved during the same period in the previous year.

While the March 2019 EPS for this company is anticipated to go down to $0.68 compared to the $0.76 recorded the same period last year, its 2020 EPS is projected to get a 49.46% boost. With that estimate, Vertex is expected to reach its long-term annual earnings growth rate of 53.86%.

How can investors be sure that Vertex continues with its remarkable progress?

The company's moves in the past months have been quite promising. A major factor that could guarantee its success is its dominance in the CF market. At the moment, Vertex has three approved CF drugs available in the market: Kalydeco, Orkambi, and Symdeko.

Of these three, two are already considered as blockbuster products while Symdeko is poised to hit the $1 billion yearly sales mark this year.

Another promising reason to invest in Vertex is its move to expand the addressable CF market it currently covers. If the company succeeds in cornering the market for treating younger patients, then its target population will increase from 39,000 to 44,000.

Vertex is also working towards gaining approval for a triple-drug combo this year. The biotech company projects an additional 24,000 patients globally to benefit from this triple-drug regimen.

Should all these plans fall into place, Vertex would see a 75% expansion on its addressable CF market in the years to come.

Although CF has been the focus of Vertex in the previous years, the company also intends to widen its scope and plans to conduct early-stage clinical studies for at least two new diseases this year.

This move would prove to be beneficial in the long-term considering the decision of AbbVie Inc (ABBV) to join the triple-drug CF race. So far, AbbVie has a long way to go before it can catch up with Vertex's progress in this arena especially since the latter practically has a monopoly as it alone offers the drugs that can treat the underlying causes of CF.

Vertex's collaboration with CRISPR Therapeutics (CRSP) on gene-editing treatments, which aim to treat rare blood disorders beta-thalassemia and sickle cell disease, is yet another promising development for the company.

All in all, Vertex is a good biotech stock to invest in today. However, its plans are not foolproof.

There remains the risk that its pipeline candidates fail at clinical trials or that the company loses its bids for regulatory approvals. Nonetheless, it's a promising stock to add to your portfolio especially since the company has more than doubled its stock in the past two years.

High risk, high gain. Welcome to the world of biotech stocks.

 

 

https://www.madhedgefundtrader.com/wp-content/uploads/2019/03/kalydeco.png 358 604 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-03-27 01:07:082019-07-09 03:59:35Jump on the Vertex Bandwagon
Mad Hedge Fund Trader

Eleventh Year Anniversary of the Mad Hedge Fund Trader

Diary, Newsletter

The Diary of a Mad Hedge Fund Trader is now celebrating its 11th year of publication.

During this time, I have religiously pumped out 1,500 words a day, or eight double-spaced typed pages, of original, independent-minded, hard-hitting, and often wickedly funny research.

I’ve been covering stocks, bonds, commodities, energy, precious metals, real estate, and agricultural products.

You’ve been kept up on my travels around the world and listened in on my conversations with those who drive the financial markets.

I also occasionally opine on politics, but only when it has a direct market impact, such as with the recent administration's economic and trade policies.

The site now contains over 11 million words or 13 times the length of Tolstoy’s epic War and Peace.

Unfortunately, it feels like I have written on every possible topic at least 100 times over.

So, I am reaching out to you, the reader, to suggest new areas of research that I may have missed until now which you believe justify further investigation.

Please send any and all ideas directly to me at support@madhedgefundtrader.com/, and put “RESEARCH IDEA” in the subject line.

The great thing about running an online business is that I can evolve it to meet your needs on a daily basis.

Many of the new products and services that I have introduced since 2008 have come at your suggestion. That has enabled me to improve the product’s quality to your benefit.

This originally started out as a daily email to my hedge fund investors giving them an update on fast market-moving events. That was at a time when the financial markets were in free fall and the end of the world seemed near.

Here’s a good trading rule of thumb: Usually, the world doesn’t end. History doesn’t repeat itself, but it certainly rhymes.

The daily emails gave me the scalability that I so desperately needed. Today’s global mega enterprise grew from there. Today, the Diary of a Mad Hedge Fund Trader and its Global Trading Dispatch is read in over 140 countries by 24,000 followers.

I’m weak in North Korea and Mali, in both cases due to the lack of electricity. But that may change.

If you want to read my first pitiful attempt at a post, please click here for my February 1, 2008 post.   

It urged readers to buy gold at $950 (it soared to $1,920), and buy the Euro at $1.50 (it went to $1.60).

Now you know why this letter has become so outrageously popular.

Unfortunately, I also recommended that they sell bonds short. I wasn’t wrong on that one, just early, about eight years too early.

I always get asked how long will I keep doing this?

The government tells me that the latest I can start drawing down on my retirement funds and Social Security is 70. That’s some three years off for me.

Given the absolute blast I have doing this job, that is highly unlikely. Take a look at the testimonials I get only an almost daily basis and you’ll see why this business is so hard to walk away from (click here for those).  

In the end, you are going to have to pry my cold dead fingers off of this keyboard to get me to give up.

Fiat Lux (let there be light).

https://www.madhedgefundtrader.com/wp-content/uploads/2017/10/john-suit-e1507749585324.jpg 201 300 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-03-27 01:06:102019-07-09 03:59:50Eleventh Year Anniversary of the Mad Hedge Fund Trader
Mad Hedge Fund Trader

The Death of Another Startup

Tech Letter

In a story that starts across the pond in Watford, England, BevMo! look-alike wine retailer Majestic Wine (WINE.L) has landed itself on the endangered species list.

If you don’t know, Majestic Wine is the largest specialty wine retailer in Britain.

The company revealed it would shutter most domestic locations and change its name to the internet wine distributor it bought in 2015 called Naked Wines.

The news is another glaring reminder that niche retailers have been muscled out of the picture and don't possess the business model to compete in the most dynamic and innovative sector in the world – groceries and the ecommerce surrounding it.

America isn’t the only country grappling with the dreaded Amazon effect.

In a drastic readjustment of strategy, Majestic Wine has given up on its physical presence choosing to up their investment in the online space before the window of opportunity closes.

The decision to bet the ranch on its Naked Wines online division and the subsequent news of the restructuring hit shares hard dropping 10%.

As of today, Naked Wines loses money as it attempts to lure in new online customers, and the higher costs have hit the bottom line.

The downfall of companies such as Majestic Wine directly correlates with the success of deep discount German supermarkets Aldi and Lidl that take a refreshing surgical approach to cost and convenience.

They use data analytics to make bold decisions, but they aren’t online retailers.

Hybrid strategies are being increasingly effective at solving complicated transnational problems.

The rise of the duo has outsized ramifications for the US supermarket industry, just only a few years after coming to America, they have penetrated with success.

If I had to sum up their model, I would describe it as Whole Foods quality meets Walmart prices with a truncated catalog of items and a superstar German management team.

In 2018, Aldi had already captured over 3% of market share in six of eight American markets, while Lidl had seized 3% of market share in five and seven markets.

This might not seem impressive in the world of supermarkets, but this is a resounding victory, it usually takes more time to convince new shoppers to switch their allegiance.

Not only have they made inroads in the US market, but they are the fastest-growing supermarkets by market share in Britain.

Much of the blame of Majestic Wine’s demise can be levied on these deep discount upstarts that act in real time allowing management to seamlessly shift products, alter floor designs, and capitalize on operational efficiencies on the ground.

Aldi plans to ramp up its British operations by remodeling the current 1,800 stores and open another 400 stores by 2022.

Up to 20% of products are continuously changing, giving another nod to the efficient management team in place.

They plan to offer 40% more prepared foods and wholesale changes in the business model are a hallmark of the company.

Covertly, they have single-handedly crushed the competitive advantage for Majestic Wine by offering medium-tiered wines for as little as $2.

And the $2 price point is not just a teaser rate, their wine selection is stocked full of options of $2 to $4 making it strenuous to compete on price.

You don’t need a full-blown online operation if management systemically executes and these two are proof.

Consumers are voting with their feet for Aldi and Lidl with British market share doubling since 2012 while every other supermarket has flatlined or decreased.

Some of the tactics spearheading the new jolt of positivity are minimizing staff while implementing a cozy design layout making it possible to conclude shopping in a streamlined fashion.

They are pedantically selective in what products they sell by offering only 1,750 products compared to big-box supermarkets that routinely sell up to 40,000 products.

Why sell 10 versions of ketchup or 50 types of flavored soda?

Being able to truncate the floor space by not wasting it with unlimited choices allows the company to deliver cost savings back to the customers.

They have also gone the Amazon route by producing an in-house brand by sourcing local ingredients and again, seeking to deliver back savings to the consumer.

The smaller space of the stores means shelves are less deep and items leave quickly, a specialized team is in place to refill products as quickly as possible.

The employees are also benefiting from this scheme by becoming the highest paid grocery staff in England surpassing the average industry wage by more than $2 more per hour.

Effectively, Lidl and Aldi are cherry-picking the industries' best practices then marrying it up with big tech’s best practices, and executing on a superior level to rave reviews from the consumer from America, Britain, and continental Europe.

Applying data analytics to reformulate strategy can be used for a recipe for success instead of copying Amazon.com.

The waters are treacherous for Majestic Wine as reverse globalization cast a dark cloud over consumer sentiment with Brexit causing the British pound to materially weaken stripping Brits of discretionary income.

The currency weakness has increased import costs of wine and an immediate threat of a hard Brexit forced the firm to import an extra 5 million to 8 million pounds of stock guaranteeing it is hedged against any delivery bottlenecks in the case of a calamitous “no deal.”

If Brexit does leave the European Union without a deal, tariffs will be slapped on imports the next day amongst other headaches.

Just as heinous, a “no deal” will force wine companies to fill out more than 600,000 additional forms that will cost the wine industry £70 million, and the need to carry out thousands of individual laboratory tests on all wine imports.

UK wine inspectors will face an immediate uptick in workloads with every handwritten VI-1 form needing to be analyzed and stamped before wine can enter from Europe.

If you visit Britain this summer, expect pricier spirits, expect more Lidls and Aldis in the area, and short the new e-commerce firm Naked Wines on every rally on the London Stock Exchange.

 

 

 

 

THE CALM BEFORE THE STORM

https://www.madhedgefundtrader.com/wp-content/uploads/2019/03/majestic.png 439 641 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-03-27 01:06:032019-07-10 21:38:23The Death of Another Startup
Mad Hedge Fund Trader

March 27, 2019 - Quote of the Day

Tech Letter

“We're running the most dangerous experiment in history right now, which is to see how much carbon dioxide the atmosphere... can handle before there is an environmental catastrophe.” – Said Founder and CEO of Tesla Elon Musk

https://www.madhedgefundtrader.com/wp-content/uploads/2019/03/elon-musk.png 304 397 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-03-27 01:05:582019-07-10 21:38:29March 27, 2019 - Quote of the Day
Page 2 of 17‹1234›»

tastytrade, Inc. (“tastytrade”) has entered into a Marketing Agreement with Mad Hedge Fund Trader (“Marketing Agent”) whereby tastytrade pays compensation to Marketing Agent to recommend tastytrade’s brokerage services. The existence of this Marketing Agreement should not be deemed as an endorsement or recommendation of Marketing Agent by tastytrade and/or any of its affiliated companies. Neither tastytrade nor any of its affiliated companies is responsible for the privacy practices of Marketing Agent or this website. tastytrade does not warrant the accuracy or content of the products or services offered by Marketing Agent or this website. Marketing Agent is independent and is not an affiliate of tastytrade. 

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2025. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
  • Privacy Policy
  • Disclaimer
  • FAQ
Scroll to top